AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32079480 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ETT results
Number of subjects: 5214
Study 32079480 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic ETT results
Number of subjects: 5214
Study 32079480 — intervention group
Group type: EXPERIMENTAL
Intervention: Nondiagnostic ETT results
Number of subjects: 5214
Study 32079480 — intervention group
Group type: EXPERIMENTAL
Intervention: Equivocal ETT results
Number of subjects: 5214
Study 35034478 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandplay therapy
Number of subjects: 40
Study 35034478 — intervention group
Group type: COMPARATOR
Intervention: Glucocorticoid, immunosuppressant and other drugs (Control Group)
Number of subjects: 40
Study 33730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg to 100 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg to 200 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg to 200 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg to 100 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg to 100 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: COMPARATOR
Intervention: Placebo 100 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: COMPARATOR
Intervention: Placebo 200 mg
Number of subjects: 0
Study 33730977 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg to 200 mg
Number of subjects: 0
Study 36507329 — intervention group
Group type: EXPERIMENTAL
Intervention: H2 inhalation therapy
Number of subjects: 65
Study 36507329 — intervention group
Group type: COMPARATOR
Intervention: Control (air inhalation)
Number of subjects: 65
Study 33256220 — intervention group
Group type: EXPERIMENTAL
Intervention: Matcha Green Tea Powder (3g per day)
Number of subjects: 61
Study 33256220 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder
Number of subjects: 61
Study 36350049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco treatment intervention offered during lung cancer screening at multiple clinical timepoints (RP1, RP2, RP3)
Number of subjects: 177
Study 36350049 — intervention group
Group type: COMPARATOR
Intervention: Recruitment point 1 (RP1)
Number of subjects: 177
Study 36350049 — intervention group
Group type: COMPARATOR
Intervention: Recruitment point 2 (RP2)
Number of subjects: 177
Study 36350049 — intervention group
Group type: COMPARATOR
Intervention: Recruitment point 3 (RP3)
Number of subjects: 177
Study 32719050 — intervention group
Group type: EXPERIMENTAL
Intervention: Online evidence-based medicine (EBM) supplement
Number of subjects: 34
Study 34428646 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxy selenomethionine (OH‐SeMet) supplementation at 0.2, 0.4, 0.6, and 0.8 mg/kg
Number of subjects: 375
Study 34428646 — intervention group
Group type: COMPARATOR
Intervention: Control group with 0.0 mg/kg Se
Number of subjects: 375
Study 32201122 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (steroid)
Number of subjects: 24
Study 32201122 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer solution (placebo)
Number of subjects: 24
Study 33888595 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision-making
Number of subjects: 1000
Study 33888595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudged information
Number of subjects: 1000
Study 33888595 — intervention group
Group type: COMPARATOR
Intervention: No involvement
Number of subjects: 1000
Study 33888595 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-treatable cancer diagnosis
Number of subjects: 1000
Study 34835970 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc deficiency defined as serum Zn concentration <9.9 µmol/L
Number of subjects: 278
Study 34835970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary Zn intake
Number of subjects: 278
Study 616082294 — intervention group
Group type: EXPERIMENTAL
Intervention: New high viscosity formula (OGD, Refresh Optive Gel Drops, Allergan)
Number of subjects: 93
Study 616082294 — intervention group
Group type: COMPARATOR
Intervention: Systane Gel Drops (SGD, Alcon)
Number of subjects: 93
Study 616082294 — intervention group
Group type: COMPARATOR
Intervention: Genteal Lubricant Gel Drops (GGD, Novartis)
Number of subjects: 93
Study 36027785 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness therapy
Number of subjects: 75
Study 36027785 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 75
Study 32485294 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (0.8 ng/kg body weight)
Number of subjects: 37
Study 32485294 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 37
Study 32485294 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS
Number of subjects: 37
Study 34330043 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-lesson unguided online treatment program targeting rumination and worry
Number of subjects: 26
Study 36109694 — intervention group
Group type: EXPERIMENTAL
Intervention: Link-me intervention (Decision Support Tool for mental health care)
Number of subjects: 1671
Study 34108036 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication monitor reminders and differentiated care (Wisepill evriMED 1000)
Number of subjects: 2610
Study 34108036 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (medication monitors for adherence tracking, TB education, normal clinic follow-up)
Number of subjects: 2610
Study 32493213 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Supreme
Number of subjects: 100
Study 32493213 — intervention group
Group type: EXPERIMENTAL
Intervention: I-gel
Number of subjects: 100
Study 32493213 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 100
Study 34730866 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 115
Study 34730866 — intervention group
Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 115
Study 33252635 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.33-mm core microbiopsy
Number of subjects: 15
Study 33252635 — intervention group
Group type: COMPARATOR
Intervention: Erbium-YAG laser treatment
Number of subjects: 15
Study 32238517 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry funded trials
Number of subjects: 96
Study 32238517 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials over time (1998-2008-2018)
Number of subjects: 96
Study 35861247 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to conflicting health information
Number of subjects: 2716
Study 35861247 — intervention group
Group type: COMPARATOR
Intervention: Exposure to health news stories and social media posts without conflicting information
Number of subjects: 2716
Study 34210941 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine (CHX)
Number of subjects: 57
Study 34210941 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 32985994 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS intervention (behavior change theory‐informed, automated, semi‐interactive SMS)
Number of subjects: 110
Study 32985994 — intervention group
Group type: COMPARATOR
Intervention: Control (no SMS)
Number of subjects: 110
Study 34668048 — intervention group
Group type: EXPERIMENTAL
Intervention: Readiness for Discharge (RFD) Scale assessment
Number of subjects: 122
Study 34668048 — intervention group
Group type: EXPERIMENTAL
Intervention: RFD Scale scoring
Number of subjects: 122
Study 32611102 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional nonlocal wiring to randomly selected nodes
Number of subjects: 0
Study 32611102 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower coupling strength
Number of subjects: 0
Study 32611102 — intervention group
Group type: EXPERIMENTAL
Intervention: Suitable choice of switching times, coupling strengths, and number of nonlocal links
Number of subjects: 0
Study 32611102 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomly switching nonlocal links
Number of subjects: 0
Study 32611102 — intervention group
Group type: COMPARATOR
Intervention: Static nonlocal wirings
Number of subjects: 0
Study 32611102 — intervention group
Group type: COMPARATOR
Intervention: Absence of nonlocal wirings
Number of subjects: 0
Study 35241087 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR3680 (80mg, 160mg, 240mg daily)
Number of subjects: 197
Study 35241087 — intervention group
Group type: EXPERIMENTAL
Intervention: SHR3680 (40mg to 480mg daily)
Number of subjects: 197
Study 32716589 — intervention group
Group type: EXPERIMENTAL
Intervention: Platform-switched abutment (test)
Number of subjects: 32
Study 32716589 — intervention group
Group type: COMPARATOR
Intervention: Platform-matching abutment (control)
Number of subjects: 32
Study 32716589 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-loaded implants
Number of subjects: 32
Study 32716589 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 32
Study 35114534 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoluminal radiofrequency ablation and metal stent implantation
Number of subjects: 0
Study 35114534 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 33960504 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paclitaxel 615 mg/m2 with encequidar 15 mg
Number of subjects: 42
Study 33960504 — intervention group
Group type: COMPARATOR
Intervention: Intravenous paclitaxel 80 mg/m2
Number of subjects: 42
Study 32324017 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental emotional suppression (suppressing affective state)
Number of subjects: 214
Study 32324017 — intervention group
Group type: COMPARATOR
Intervention: Control condition (acting naturally)
Number of subjects: 214
Study 36048234 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness
Number of subjects: 85
Study 33789908 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NMR analytes and their changes
Number of subjects: 2590
Study 33789908 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline 2-hour glucose
Number of subjects: 2590
Study 33789908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sophisticated machine learning algorithms
Number of subjects: 2590
Study 33789908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard lipids and demographic and glycemic traits
Number of subjects: 2590
Study 34724678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-Assisted Spinal Anesthesia (USAS)
Number of subjects: 114
Study 34724678 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-Guided Spinal Anesthesia (USRTG)
Number of subjects: 114
Study 34465357 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive care by a multidisciplinary care team (MDCT)
Number of subjects: 98
Study 34465357 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 98
Study 35935255 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital training system
Number of subjects: 24
Study 35935255 — intervention group
Group type: COMPARATOR
Intervention: Control group (lectures without digital technologies)
Number of subjects: 24
Study 34957952 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 drops of oral synbiotic daily along with phototherapy
Number of subjects: 194
Study 34787778 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 30 mg with daily TMZ and RT
Number of subjects: 55
Study 34787778 — intervention group
Group type: EXPERIMENTAL
Intervention: Afatinib 40 mg with RT alone
Number of subjects: 55
Study 34787778 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen M (Afatinib + TMZ + RT)
Number of subjects: 55
Study 34787778 — intervention group
Group type: EXPERIMENTAL
Intervention: Regimen U (Afatinib + RT)
Number of subjects: 55
Study 34787778 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 55
Study 32970697 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily self-administered vaginal progesterone (VP)
Number of subjects: 140
Study 32970697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 34595960 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological inoculation (PI) + health information (experimental)
Number of subjects: 0
Study 34595960 — intervention group
Group type: COMPARATOR
Intervention: Health information alone (control)
Number of subjects: 0
Study 33866656 — intervention group
Group type: EXPERIMENTAL
Intervention: Any treatment received
Number of subjects: 5117
Study 33866656 — intervention group
Group type: EXPERIMENTAL
Intervention: Care from qualified providers (doctor, nurse, midwife, trained community health worker, pharmacist) within 24 hours
Number of subjects: 5117
Study 33866656 — intervention group
Group type: COMPARATOR
Intervention: Distance to primary health facility
Number of subjects: 5117
Study 33866656 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptoms indicative of pneumonia and malaria
Number of subjects: 5117
Study 33866656 — intervention group
Group type: COMPARATOR
Intervention: Socio-demographic factors (household wealth, maternal education)
Number of subjects: 5117
Study 35249535 — intervention group
Group type: EXPERIMENTAL
Intervention: Different cover letter content and incentives ($20 or $40)
Number of subjects: 960
Study 33636650 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-healing intervention (14 sessions of 90-min each)
Number of subjects: 30
Study 33636650 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 37380728 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin plus basal‐bolus insulin (DAPA group)
Number of subjects: 250
Study 37380728 — intervention group
Group type: COMPARATOR
Intervention: Basal‐bolus insulin alone (INSULIN group)
Number of subjects: 250
Study 34197281 — intervention group
Group type: EXPERIMENTAL
Intervention: V-01 vaccine (10, 25, and 50 µg)
Number of subjects: 0
Study 34197281 — intervention group
Group type: EXPERIMENTAL
Intervention: V-01 vaccine (10 µg) subgroup and elderly participants
Number of subjects: 0
Study 34197281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32369298 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical spray of papaverine on harvested LIMA
Number of subjects: 40
Study 32369298 — intervention group
Group type: EXPERIMENTAL
Intervention: Perivascular injection of papaverine
Number of subjects: 40
Study 32369298 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both methods
Number of subjects: 40
Study 34676918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionomeric sealant (IS) (Clinpro XT Varnish)
Number of subjects: 121
Study 34676918 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-phosphate/fluoride varnish (Ca/PO4‐ /F‐ varnish) (Clinpro White Varnish)
Number of subjects: 121
Study 34676918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 34676918 — intervention group
Group type: EXPERIMENTAL
Intervention: Ionomeric sealant (IS)
Number of subjects: 121
Study 34676918 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-phosphate/fluoride varnish (Ca/PO4‐ /F‐ varnish)
Number of subjects: 121
Study 32300897 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive exercise group (PEG)
Number of subjects: 28
Study 32300897 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 28
Study 36084898 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health worker (CHW)‐delivered intervention
Number of subjects: 110
Study 36084898 — intervention group
Group type: COMPARATOR
Intervention: Usual cancer care
Number of subjects: 110
Study 32179010 — intervention group
Group type: EXPERIMENTAL
Intervention: Stimulated Cycle (STC)
Number of subjects: 119
Study 36360629 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body electromyostimulation (WB-EMS)
Number of subjects: 20
Study 36360629 — intervention group
Group type: COMPARATOR
Intervention: Regular training without WB-EMS
Number of subjects: 20
Study 32158738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment with biopsychosocial perceived etiology
Number of subjects: 0
Study 32158738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with biopsychosocial perceived etiology
Number of subjects: 0
Study 32158738 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment with biomedical perceived etiology
Number of subjects: 0
Study 32158738 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment with biomedical perceived etiology
Number of subjects: 0
Study 32158738 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment information wording matching perceived etiology
Number of subjects: 0
Study 36216984 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent–Child Interaction Therapy‐Emotion Development (PCIT‐ED)
Number of subjects: 229
Study 36216984 — intervention group
Group type: COMPARATOR
Intervention: Waitlist (WL)
Number of subjects: 229
Study 34601450 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided, eight-week mindfulness program delivered online
Number of subjects: 0
Study 34601450 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 0
Study 32711568 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine
Number of subjects: 0
Study 32711568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33827631 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing aids intervention
Number of subjects: 464
Study 35575293 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasudil
Number of subjects: 25
Study 35575293 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study 32888121 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythm control with antiarrhythmic drugs (AADs)
Number of subjects: 210
Study 32888121 — intervention group
Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 210
Study 32785213 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 µg BNT162b1
Number of subjects: 45
Study 32785213 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 µg BNT162b1
Number of subjects: 45
Study 32785213 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 µg BNT162b1
Number of subjects: 45
Study 32785213 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 34530210 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive recruitment strategies (word-of-mouth, flyers)
Number of subjects: 821
Study 34530210 — intervention group
Group type: COMPARATOR
Intervention: Proactive recruitment strategies (direct invitations)
Number of subjects: 821
Study 34530210 — intervention group
Group type: EXPERIMENTAL
Intervention: Word-of-mouth
Number of subjects: 821
Study 34530210 — intervention group
Group type: EXPERIMENTAL
Intervention: Flyer distribution (paid strategy)
Number of subjects: 821
Study 34530210 — intervention group
Group type: EXPERIMENTAL
Intervention: Newspaper ads (paid strategy)
Number of subjects: 821
Study 34530210 — intervention group
Group type: EXPERIMENTAL
Intervention: Online advertisements (paid strategy)
Number of subjects: 821
Study 34530210 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio and television ads (paid strategy)
Number of subjects: 821
Study 34002557 — intervention group
Group type: EXPERIMENTAL
Intervention: Scalp acupuncture combined with lower-limb intelligent feedback training
Number of subjects: 154
Study 34002557 — intervention group
Group type: COMPARATOR
Intervention: Lower-limb intelligent feedback training alone
Number of subjects: 154
Study 32815416 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic-dose anticoagulation with low-molecular-weight heparin or unfractionated heparin
Number of subjects: 0
Study 32815416 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 36125566 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular bone score (TBS) Hip at total hip
Number of subjects: 132
Study 36125566 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular bone score (TBS) Hip at femoral neck
Number of subjects: 132
Study 36125566 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular bone score (TBS) Hip at greater trochanter
Number of subjects: 132
Study 36125566 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabecular bone score (TBS) at lumbar spine
Number of subjects: 132
Study 36125566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers (BTMs)
Number of subjects: 132
Study 35923359 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oxygen therapy (STOT)
Number of subjects: 243
Study 35923359 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term oxygen therapy (STOT) for more than one month or repeated prescriptions
Number of subjects: 243
Study 32024447 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet self-help blended with face-to-face therapy
Number of subjects: 11
Study 35442766 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab (200 mg every 3 weeks)
Number of subjects: 512
Study 35442766 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (investigator's choice of paclitaxel, docetaxel, or irinotecan)
Number of subjects: 512
Study 33825892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib + Temozolomide (TMZ) (arm A)
Number of subjects: 24
Study 33825892 — intervention group
Group type: COMPARATOR
Intervention: Temozolomide (TMZ) (arm B)
Number of subjects: 24
Study 33825892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib (arm C)
Number of subjects: 24
Study 32338468 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-frame SMS
Number of subjects: 211
Study 32338468 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-frame SMS
Number of subjects: 211
Study 32338468 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study 36348192 — intervention group
Group type: EXPERIMENTAL
Intervention: PWLHIV
Number of subjects: 500
Study 36348192 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship factors (unmarried, non-cohabitating, shorter, polygamous relationships, HIV non-disclosure, verbal abuse)
Number of subjects: 500
Study 36348192 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews with 45 women and 45 men
Number of subjects: 500
Study 33415790 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness microintervention
Number of subjects: 202